|
Xeloda® (capecitabine) Coverage/ Reimbursement
Xeloda (capecitabine) DIN 02238454 (500 mg), 02238453 (150 mg)
Roche Patient Assistance Program 1-888-748-8926
The Roche Patient Assistance Program is a service for patients who require reimbursement and infusion support for Roche oncology, hematology and rheumatology therapies that are approved by Health Canada. Services include call centre support; financial assistance; reimbursement navigation; infusion coordination (if required); and coordination of distribution and pharmacy services. For more information about the program, please call toll-free 1-888-748-8926. For oncologists or hematologists who wish to print off a Patient Enrollment Form, please click here.
Xeloda is an eligible benefit through most private insurance plans, provincial drug benefit programs/ provincial cancer agencies and federal drug programs. The sidebar menu allows you to access specific information on coverage of Xeloda by private insurance plans, the individual provincial drug benefit/ provincial cancer agency programs and through the federal drug plans. Information includes coverage/ reimbursement criteria and guidelines, limited use codes and criteria, special authorization forms, instructions and other resources. Click on the plan or program name to access.
Xeloda (capecitabine) is indicated for the treatment of:
Colorectal Cancer- Adjuvant treatment of stage III (Dukes’ stage C) colon cancer based on the promising clinical evidence that it may be useful in the treatment of patients with this serious disease
- First-line treatment of metastatic colorectal cancer
Breast Cancer- In combination with docetaxel for advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy
- As monotherapy for advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.
Xeloda is contraindicated in patients who have a known hypersensitivity to capecitabine or to any of its components or to 5-fluorouracil and in patients with severe renal impairment (calculated creatinine clearance below 30 mL/min, or 0.5 mL/s). As with other fluoropyrimidines, Xeloda is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Contraindications for docetaxel also apply to the Xeloda® plus docetaxel combination.
In adjuvant colon cancer treatment, frequently reported adverse events included hand-and-foot syndrome (60%), diarrhea (46%), nausea (22%), vomiting (14%), stomatitis (22%), fatigue (15 %) and lethargy (10%). In metastatic colon cancer, frequently reported adverse events included lymphopenia (93%), anemia (80%), hand-and-foot syndrome (53%), hyperbilirubinemia (49%), diarrhea (49%), nausea (38%), fatigue/weakness (32%), stomatitis (25%), dermatitis (24%), vomiting (23%), neutropenia (21%), decreased appetite (20%), thrombocytopenia (20%), abdominal pain (17%).
Reference: Xeloda Product Monograph
Resources for Healthcare Professionals and Patients
Colorectal Cancer Association of Canada Web Site
Wellspring Web Site
Canadian Breast Cancer Network
Cancer Advocacy Coalition Canada Web Site
Xeloda Product Monograph click on Health Professional Information for the full product monograph
®Registered Trade-Mark of Hoffmann-La Roche Limited
|
